Philips (NYSE: PHG) wins full shareholder backing at 2026 AGM
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Royal Philips reported that shareholders approved all proposals at its 2026 Annual General Meeting. Decisions included appointing John DeFord to the Supervisory Board and re-appointing Paul Stoffels, Herna Verhagen and Sanjay Poonen to the Supervisory Board.
Shareholders also re-appointed Roy Jakobs as President/CEO, Chairman and member of the Board of Management and granted discharge to both the Board of Management and Supervisory Board. Philips highlighted its position as a global health technology company with 2025 sales of EUR 18 billion and around 64,300 employees worldwide.
Positive
- None.
Negative
- None.
Key Figures
2025 sales: EUR 18 billion
Employees: 64,300 employees
AGM year: 2026 AGM
+1 more
4 metrics
2025 sales
EUR 18 billion
Company-wide sales in 2025
Employees
64,300 employees
Global workforce as of 2025
AGM year
2026 AGM
Annual General Meeting at which all proposals were approved
Effective date of appointments
May 8, 2026
Effective date for new and re-appointed board members
Key Terms
Annual General Meeting of Shareholders (AGM), Supervisory Board, Board of Management, discharge, +1 more
5 terms
Supervisory Board financial
"Appointment of John DeFord ... as new member of the Supervisory Board"
A supervisory board is an independent oversight body that watches over a company’s executive managers, reviews strategy, approves major decisions, and hires or removes top executives. It acts like an impartial group of guardians or referees who make sure managers are running the business responsibly and within agreed rules. Investors care because strong oversight can reduce risks, improve accountability, and protect long‑term shareholder value.
Board of Management financial
"Re-appointment of Roy Jakobs ... as President/CEO and Chairman and member of the Board of Management"
The board of management is the team of senior executives who run a company day-to-day, set and carry out its strategy, and make operational decisions about products, costs and investments. Investors care because this group acts like the company’s driver and navigator: their choices determine financial results, risk levels and how capital is used, so their experience, incentives and track record directly affect the value and future prospects of an investment.
discharge financial
"Discharge of the members of the Board of Management, and of the members of the Supervisory Board"
health technology technical
"a global leader in health technology"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________
FORM 6-K
____________________________________________________________________________
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
May 8, 2026
____________________________________________________________________________
KONINKLIJKE PHILIPS N.V.
(Exact name of registrant as specified in its charter)
____________________________________________________________________________
Royal Philips
(Translation of registrant’s name into English)
The Netherlands
(Jurisdiction of incorporation or organization)
Prinses Irenestraat 59, 1077 WV Amsterdam, The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission:
M.J. van Ginneken
Koninklijke Philips N.V.
Prinses Irenestraat 59
1077 WV Amsterdam – The Netherlands
This report comprises a copy of the following press release:
“Philips shareholders approve all proposals at the AGM 2026”, dated May 8, 2026.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 8th day of May 2026.
KONINKLIJKE PHILIPS N.V.
/s/ M.J. van Ginneken
(Chief Legal Officer)
(Chief Legal Officer)
Media Release
May 8, 2026
Philips shareholders approve all proposals at the AGM 2026
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including:
•Appointment of John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.
•Re-appointment of Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board, with effect from May 8, 2026.
•Re-appointment of Roy Jakobs (Dutch/German, 1974) as President/CEO and Chairman and member of the Board of Management, with effect from May 8, 2026.
•Discharge of the members of the Board of Management, and of the members of the Supervisory Board.
Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board and the Board of Management, we welcome John DeFord to the Supervisory Board. He brings extensive global MedTech experience and deep expertise across innovation, interventional domains, and regulatory and quality environments. We also sincerely thank Marc Harrison, who's second term ended at the end of the AGM, for his valued guidance and contributions over the past eight years. The re-appointments of Paul Stoffels, Herna Verhagen and Sanjay Poonen provide a strong combination of expertise and important continuity to support Philips as it advances its next strategic phase.”
Mr Sijbesma added: “We congratulate Roy Jakobs on his re-appointment as President/CEO and Chairman of the Board of Management. We have full confidence in his leadership to successfully lead Philips through its next phase as the company continues to strengthen execution, innovation and performance, and advance its strategic priorities.”
Roy Jakobs, CEO of Royal Philips, said: “I appreciate the continued trust and support of our shareholders and Supervisory Board. I would like to thank John DeFord for joining. Together with other Supervisory Board members, he brings valuable expertise to support management with strong oversight and guidance. I look forward to our continued close collaboration and am
excited to deliver sustainable value for Philips and all its stakeholders as we drive profitable growth.”
Further details about the dividend can be found via this link, and additional information on the composition of the Board of Management, the Executive Committee and the Supervisory Board can be found here. Philips’ 2025 financial statements are included in its Annual Report 2025 that was published on February 19, 2026. A full overview of the resolutions taken and more information about Philips’ AGM 2026 is available via this link.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 614869261
E-mail: Michael.Fuchs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
FAQ
Who joined Philips (PHG) Supervisory Board at the 2026 AGM?
Shareholders approved the appointment of John DeFord as a new member of Philips’ Supervisory Board, effective May 8, 2026. The company emphasized his global MedTech experience and expertise in innovation, interventional domains, and regulatory and quality environments as valuable additions to board oversight.
Was Philips CEO Roy Jakobs re-appointed at the 2026 AGM?
Yes. Shareholders re-appointed Roy Jakobs as President/CEO, Chairman and member of the Board of Management, effective May 8, 2026. The Supervisory Board expressed full confidence in his leadership as Philips continues its next strategic phase focused on execution, innovation and performance.
Which Supervisory Board members of Philips (PHG) were re-appointed?
Shareholders re-appointed Paul Stoffels, Herna Verhagen and Sanjay Poonen as members of the Supervisory Board, effective May 8, 2026. The Supervisory Board highlighted their combined expertise and continuity as important support for Philips’ strategy and long-term value creation.
How large is Philips’ business based on its 2025 results?
Philips reported 2025 sales of EUR 18 billion, underscoring its scale as a global health technology company. It employs approximately 64,300 people and provides sales and services in more than 100 countries across diagnostic imaging, monitoring, and personal health solutions.